Armetheon Raises $24.3 Million From Taiwan/China Investors
publication date: Feb 6, 2015
Armetheon, a San Francisco area specialty biopharma, raised $24.3 million in a Series B funding that will be used to underwrite a Phase III trial of its oral anticoagulant, tecarfarin. Participants in the financing had Taiwan/China connections. The B round was co-led by Hercules Bioventure Partners and Capital TEN II, which are affiliated with Larry Hsu, PhD, a co-founder of Idenix Labs who was born in Taiwan. Other investors included China Development Industrial Bank Healthcare, CDIB & Partners, iD SoftCapital Group of Taiwan and AmKey Ventures. More details....
Stock Symbol: (NDSQ: IDIX)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.